{"id":"intravitreal-bevacizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Endophthalmitis (intraocular infection)"},{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Cataract progression"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Floaters/vitreous opacities"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"When injected directly into the vitreous cavity of the eye, bevacizumab binds to and neutralizes VEGF, a key driver of pathological neovascularization in retinal diseases. By reducing VEGF signaling, it suppresses the growth of abnormal blood vessels and reduces vascular permeability, thereby slowing or halting disease progression in conditions characterized by excessive retinal angiogenesis.","oneSentence":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:59.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (AMD), wet form"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"},{"name":"Proliferative diabetic retinopathy (PDR)"}]},"trialDetails":[{"nctId":"NCT07481500","phase":"NA","title":"Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety","status":"NOT_YET_RECRUITING","sponsor":"Jakkrit Juhong","startDate":"2026-06","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":120},{"nctId":"NCT05217680","phase":"PHASE3","title":"Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-05-24","conditions":"Diabetic Macular Edema","enrollment":510},{"nctId":"NCT07429474","phase":"PHASE1","title":"Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2026-03-01","conditions":"Immunogenicity, Anti-drug Antibodies (ADAs)","enrollment":60},{"nctId":"NCT04634578","phase":"PHASE2","title":"Bevacizumab Treatment For Type 1 ROP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2022-05-01","conditions":"Retinopathy of Prematurity","enrollment":77},{"nctId":"NCT07338097","phase":"NA","title":"Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema","status":"ENROLLING_BY_INVITATION","sponsor":"CMH Multan Institute of Medical Sciences","startDate":"2025-09-07","conditions":"Diabetic Macular Edema (DME)","enrollment":116},{"nctId":"NCT03940690","phase":"PHASE3","title":"Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2019-10-24","conditions":"Retinal Telangiectasis, Coats Disease","enrollment":18},{"nctId":"NCT04101877","phase":"PHASE2","title":"The Sahlgrenska Anti-VEGF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2020-09-03","conditions":"Neovascular Age-related Macular Degeneration","enrollment":402},{"nctId":"NCT06952452","phase":"PHASE3","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2022-11-18","conditions":"Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT01295112","phase":"PHASE2, PHASE3","title":"Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Texas Retina Associates","startDate":"2011-05","conditions":"Non-Ischemic Central Retinal Vein Occlusion","enrollment":68},{"nctId":"NCT06850571","phase":"PHASE4","title":"Aflibercept and Bevacizumab for Diabetic Maculopathies","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-02-20","conditions":"Diabetic Maculopathy","enrollment":102},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT03648814","phase":"NA","title":"Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT","status":"RECRUITING","sponsor":"Prince of Songkla University","startDate":"2018-08-01","conditions":"Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression","enrollment":40},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT03844074","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":61},{"nctId":"NCT03834753","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2019-06-25","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":228},{"nctId":"NCT04516278","phase":"PHASE3","title":"A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2020-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":195},{"nctId":"NCT06882551","phase":"PHASE4","title":"Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients","status":"COMPLETED","sponsor":"Khyber Teaching Hospital","startDate":"2023-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":82},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT06190093","phase":"PHASE3","title":"A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2024-01-24","conditions":"Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration","enrollment":400},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT05776875","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC","status":"TERMINATED","sponsor":"Yale University","startDate":"2023-06-07","conditions":"Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT00967850","phase":"PHASE3","title":"Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2008-04","conditions":"Myopia, Choroidal Neovascularization","enrollment":56},{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT06595355","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin","status":"RECRUITING","sponsor":"Isfahan University of Medical Sciences","startDate":"2021-10-10","conditions":"Diabetic Macular Edema, Macular Edema, Retinal Neovascularization","enrollment":52},{"nctId":"NCT06559488","phase":"NA","title":"IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2018-04-02","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage","enrollment":18},{"nctId":"NCT06191094","phase":"PHASE4","title":"Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy","status":"ENROLLING_BY_INVITATION","sponsor":"University of Colorado, Denver","startDate":"2024-07-12","conditions":"Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus","enrollment":100},{"nctId":"NCT00346814","phase":"PHASE2, PHASE3","title":"Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome","status":"RECRUITING","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2007-07","conditions":"Retinopathy of Prematurity","enrollment":""},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT00406172","phase":"PHASE3","title":"Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-11","conditions":"Cystoid Macular Edema","enrollment":""},{"nctId":"NCT00496405","phase":"PHASE4","title":"Unilateral Bevacizumab for Bilateral Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2007-04","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":""},{"nctId":"NCT00418431","phase":"PHASE2, PHASE3","title":"Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Central Serous Chorioretinopathy","enrollment":""},{"nctId":"NCT00347711","phase":"PHASE3","title":"Bevacizumab and Retinal Vascular Occlusions","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-06","conditions":"Edema Macular, Vascular Occlusion","enrollment":""},{"nctId":"NCT00406744","phase":"PHASE3","title":"Efficacy of Retreatments With Intravitreal Bevacizumab","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-05","conditions":"Age Related Macular Degeneration, Choroidal Neovascularization","enrollment":20},{"nctId":"NCT00417833","phase":"PHASE2, PHASE3","title":"Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-12","conditions":"Diabetic Proliferative Retinopathy, Vascular Vein Oclussion, Choroidal Neovascularization","enrollment":""},{"nctId":"NCT00599820","phase":"PHASE3","title":"Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-11","conditions":"Angioid Streaks, Choroidal Neovascularization","enrollment":""},{"nctId":"NCT00417716","phase":"PHASE3","title":"Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-09","conditions":"Diabetes Mellitus Type 2, Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00801866","phase":"PHASE4","title":"Avastin for Post-photocoagulation Macular Edema","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-12","conditions":"Macular Edema","enrollment":""},{"nctId":"NCT00347165","phase":"PHASE2","title":"Intravitreal Bevacizumab for Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-09","conditions":"Age Related Macular Degeneration","enrollment":50},{"nctId":"NCT00406380","phase":"PHASE3","title":"Effect of Avastin in Juxtafoveal Telangiectasias","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-09","conditions":"Telangiectasis","enrollment":""},{"nctId":"NCT00600301","phase":"PHASE3","title":"Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-01","conditions":"Diffuse Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00347399","phase":"PHASE2","title":"Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-03","conditions":"Age Related Macular Degeneration","enrollment":25},{"nctId":"NCT00347698","phase":"PHASE2, PHASE3","title":"Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-03","conditions":"Diabetic Retinopathy","enrollment":""},{"nctId":"NCT00407121","phase":"PHASE3","title":"Intravitreal Bevacizumab for Inflammatory Neovascular Membranes","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-12","conditions":"Vogt Koyanagi Harada Disease, Serpiginous Choroiditis, Multifocal Choroiditis","enrollment":""},{"nctId":"NCT00804206","phase":"PHASE4","title":"Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2008-07","conditions":"Macular Edema","enrollment":15},{"nctId":"NCT00600262","phase":"PHASE2, PHASE3","title":"Intravitreal Bevacizumab for Diabetic Retinopathy","status":"TERMINATED","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2005-12","conditions":"Severe Nonproliferative, Proliferative Diabetic Retinopathy, Active Photocoagulated Diabetic Retinopathy","enrollment":""},{"nctId":"NCT05112861","phase":"PHASE3","title":"A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Outlook Therapeutics, Inc.","startDate":"2021-11-15","conditions":"Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":120},{"nctId":"NCT00390026","phase":"PHASE3","title":"The Avastin vs Visudyne for Neovascular AMD Study","status":"WITHDRAWN","sponsor":"St. Erik Eye Hospital","startDate":"2006-11","conditions":"Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT04674254","phase":"PHASE4","title":"Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-03-30","conditions":"Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy","enrollment":43},{"nctId":"NCT03211741","phase":"PHASE4","title":"Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2013-11-22","conditions":"Retinal Neovascularization, Macular Edema","enrollment":500},{"nctId":"NCT00870636","phase":"","title":"Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)","status":"NO_LONGER_AVAILABLE","sponsor":"Children's Hospital Los Angeles","startDate":"","conditions":"Retinopathy of Prematurity","enrollment":""},{"nctId":"NCT05080803","phase":"","title":"Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome","status":"COMPLETED","sponsor":"European School of Advanced Studies in Ophthalmology","startDate":"2021-06-01","conditions":"Diabetic Macular Edema","enrollment":608},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT01716026","phase":"PHASE3","title":"Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2012-10","conditions":"Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia","enrollment":66},{"nctId":"NCT04991350","phase":"PHASE4","title":"Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema","status":"TERMINATED","sponsor":"Cairo University","startDate":"2021-11-26","conditions":"Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy","enrollment":5},{"nctId":"NCT05712642","phase":"PHASE3","title":"A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-02-01","conditions":"Retinopathy of Prematurity","enrollment":19},{"nctId":"NCT01610557","phase":"PHASE2","title":"Ranibizumab and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-05","conditions":"Diabetic Macular Edema","enrollment":56},{"nctId":"NCT05582577","phase":"PHASE2, PHASE3","title":"Additional Effect of Subthreshold Micropulse Laser to Intravitreous Injection of Bevacizumab on Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-10-15","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT04812977","phase":"NA","title":"Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hayatabad Medical Complex","startDate":"2018-06-10","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":30},{"nctId":"NCT05514925","phase":"PHASE4","title":"Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy","status":"UNKNOWN","sponsor":"Khairallah Moncef","startDate":"2017-11-21","conditions":"Proliferative Diabetic Retinopathy, Vitreous Hemorrhage, Tractional Retinal Detachment","enrollment":60},{"nctId":"NCT02985619","phase":"PHASE2, PHASE3","title":"Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2016-07-21","conditions":"Diabetic Macular Edema","enrollment":100},{"nctId":"NCT05290948","phase":"PHASE2","title":"Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-03-12","conditions":"Macular Edema","enrollment":57},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT05186155","phase":"","title":"Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-01","conditions":"Retinopathy of Prematurity, Neurodevelopmental Abnormality","enrollment":510},{"nctId":"NCT02015351","phase":"NA","title":"Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2012-09","conditions":"Choroidal Neovascularization","enrollment":9},{"nctId":"NCT04827836","phase":"NA","title":"Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection","status":"COMPLETED","sponsor":"Wolfson Medical Center","startDate":"2021-07-11","conditions":"Intravitreal Injection, Pain, Subconjunctival Hemorrhage","enrollment":100},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600},{"nctId":"NCT02096874","phase":"PHASE4","title":"Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema","status":"COMPLETED","sponsor":"King Khaled Eye Specialist Hospital","startDate":"2013-06","conditions":"Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02590094","phase":"NA","title":"Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV","status":"COMPLETED","sponsor":"Panhandle Eye Group, LLP","startDate":"2015-10","conditions":"Diabetic Retinopathy","enrollment":568},{"nctId":"NCT05083689","phase":"PHASE2, PHASE3","title":"Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2021-10-06","conditions":"Diabetic Macular Edema","enrollment":62},{"nctId":"NCT05033106","phase":"PHASE3","title":"Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2020-09-01","conditions":"Retinopathy of Prematurity Both Eyes","enrollment":36},{"nctId":"NCT01969708","phase":"PHASE3","title":"Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)","status":"COMPLETED","sponsor":"The Emmes Company, LLC","startDate":"2014-09","conditions":"Central Retinal Vein Occlusion","enrollment":362},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT01571232","phase":"PHASE2","title":"Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema","status":"COMPLETED","sponsor":"Retina Macula Institute","startDate":"2012-04","conditions":"Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy","enrollment":20},{"nctId":"NCT02192970","phase":"PHASE2","title":"Bevacizumab Against Recurrent Retinal Detachment","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-01-21","conditions":"Retinal Detachment, Proliferative Vitreoretinopathy","enrollment":101},{"nctId":"NCT04800679","phase":"PHASE2","title":"Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-03-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":105},{"nctId":"NCT04119921","phase":"PHASE2, PHASE3","title":"Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2018-01-01","conditions":"DME","enrollment":26},{"nctId":"NCT04067856","phase":"NA","title":"Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery","status":"WITHDRAWN","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-01-01","conditions":"Diabetic Macular Edema, Cataract","enrollment":""},{"nctId":"NCT04619303","phase":"PHASE4","title":"Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO","status":"COMPLETED","sponsor":"Lions Eye Institute, Perth, Western Australia","startDate":"2017-02-07","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":59},{"nctId":"NCT01982435","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Justis Ehlers","startDate":"2014-06-24","conditions":"Diabetic Macular Edema","enrollment":27},{"nctId":"NCT03668054","phase":"PHASE3","title":"Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2017-02-07","conditions":"Age-Related Macular Degeneration","enrollment":22},{"nctId":"NCT04601701","phase":"NA","title":"Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2020-10-17","conditions":"Central Retinal Vein Occlusion","enrollment":100},{"nctId":"NCT04601688","phase":"NA","title":"Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.","status":"UNKNOWN","sponsor":"He Eye Hospital","startDate":"2020-10-31","conditions":"Branch Retinal Vein Occlusion","enrollment":100},{"nctId":"NCT03423823","phase":"PHASE2","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","status":"COMPLETED","sponsor":"Kapil Kapoor","startDate":"2017-07-07","conditions":"Wet Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT04511715","phase":"PHASE2, PHASE3","title":"Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-09-01","conditions":"Non-proliferative Diabetic Retinopathy","enrollment":100},{"nctId":"NCT01627249","phase":"PHASE3","title":"Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-08","conditions":"Diabetic Macular Edema","enrollment":660},{"nctId":"NCT02229175","phase":"PHASE2, PHASE3","title":"Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2021-01-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT03246152","phase":"PHASE4","title":"Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-10-23","conditions":"Diabetic Macular Edema, Ischemic Maculopathy","enrollment":31},{"nctId":"NCT04138420","phase":"","title":"Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab","status":"COMPLETED","sponsor":"Federico II University","startDate":"2017-01-25","conditions":"Exudative Age-related Macular Degeneration","enrollment":38},{"nctId":"NCT01471054","phase":"PHASE2","title":"Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma","status":"TERMINATED","sponsor":"Arman Mashayekhi","startDate":"2014-04","conditions":"Macular Edema, Cystoid Macular Edema, Uveal Melanoma","enrollment":6},{"nctId":"NCT04018833","phase":"","title":"Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bernardete Pessoa MD","startDate":"2012-01-01","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":40},{"nctId":"NCT00563940","phase":"","title":"Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2007-03","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT03974425","phase":"NA","title":"One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2016-04-01","conditions":"Diabetic Macular Edema","enrollment":37},{"nctId":"NCT01661946","phase":"PHASE3","title":"Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye","status":"COMPLETED","sponsor":"Queen's University","startDate":"2012-08","conditions":"Diabetic Macular Edema","enrollment":10},{"nctId":"NCT01170767","phase":"PHASE3","title":"French Evaluation Group Avastin Versus Lucentis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-06","conditions":"Age Related Macular Degeneration","enrollment":501},{"nctId":"NCT03340610","phase":"PHASE4","title":"IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT01027468","phase":"NA","title":"Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2009-08","conditions":"Neovascular Age-related Macular Degeneration","enrollment":160},{"nctId":"NCT03892434","phase":"PHASE4","title":"Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO","status":"UNKNOWN","sponsor":"Yeungnam University College of Medicine","startDate":"2019-03-18","conditions":"Branch Retinal Vein Occlusion With Macular Edema","enrollment":40},{"nctId":"NCT02471651","phase":"PHASE4","title":"Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3004,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin"],"phase":"marketed","status":"active","brandName":"Intravitreal bevacizumab","genericName":"Intravitreal bevacizumab","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye. Used for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}